GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

There were still 32,000 new cases of HIV in the U.S. in 2022. And about thousands of people still die annually from AIDS. HIV ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

Shares in the company rose on Wednesday morning as a result, lifting to their highest level for more than a year.

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or ...

Leaders in HIV research highlighted the critical role of that research has played in advancing HIV science over the past 40 years. In a commentary in Nature Medicine, they explained how U.S.-funded ...

When President Donald Trump issued an executive order suspending all foreign aid to South Africa, in January this year, we immediately set about finding solutions. Among the most pressing was to ...

GSK lifted profit expectations for the year after the pharma group's sales were boosted by bumper demand for HIV and cancer ...

Through a US$ 29 million grant, South Africa will receive enough medicine to provide HIV prevention to 450 000 people at high ...